Detalhe da pesquisa
1.
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Nature
; 597(7878): 732-737, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34526717
2.
Inhibition of nonsense-mediated decay rescues p53ß/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers.
J Biol Chem
; 297(5): 101163, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34481841
3.
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
J Thorac Oncol
; 19(1): 106-118, 2024 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37678511
4.
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
Clin Cancer Res
; 29(7): 1292-1304, 2023 04 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36595561
5.
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
Cancer Cell
; 41(2): 340-355.e6, 2023 02 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36787696
6.
MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.
Cancer Cell
; 41(7): 1363-1380.e7, 2023 07 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37327788
7.
STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition.
Clin Cancer Res
; 27(6): 1720-1733, 2021 03 15.
Artigo
Inglês
| MEDLINE | ID: mdl-33323404
8.
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Cancer Prev Res (Phila)
; 14(3): 313-324, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33277316
9.
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components.
Sci Transl Med
; 12(559)2020 09 02.
Artigo
Inglês
| MEDLINE | ID: mdl-32878980
10.
LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma.
Cancer Res
; 79(13): 3251-3267, 2019 07 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31040157
11.
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Cancer Cell
; 36(4): 444-457.e7, 2019 10 14.
Artigo
Inglês
| MEDLINE | ID: mdl-31588020
12.
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Nat Med
; 24(5): 638-646, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29686424
13.
Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers.
Sci Transl Med
; 9(415)2017 Nov 08.
Artigo
Inglês
| MEDLINE | ID: mdl-29118262
14.
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Cancer Cell
; 37(3): 420, 2020 Mar 16.
Artigo
Inglês
| MEDLINE | ID: mdl-32183953